TRIMETHOPRIM ORAL LIQUID

Abstract: This invention is directed to an aqueous pharmaceutical composition with 1.25 mg to about 10 mg trimethoprim per mL (wt/vol) of solution and a compound of suitable acid strength to permit the dissolving of trimethoprim at the appropriate concentration, with the composition having a pH of less than 6.0. This composition is particularly useful for pediatric oral use.

Description: Title of the Invention TRIMETHOPRIM ORAL LIQUID FIELD OF THE INVENTION This invention is directed to a palatable oral solution of trimethoprim in a suitable concentration for pediatric dosing. BACKGROUND OF THE INVENTION Trimethoprim, U. S. P. (TMP) is a synthetic antibacterial agent which acts by selectively interfering with the biosynthesi of nucleic acids and proteins in bacteria. "The Pharmacological Basis of Therapeutics", 8th Edition, AG Gil an, T Rail, AS Nies P Taylor, eds., Pergamon Press. It is rapidly absorbed followin oral administration and has a half-life of 8-10 hours. It is a white to light yellow, odorless, bitter compound with very poor solubility in water and alcohol. "Analytical Profiles of Drug Substances", Vol. 7, K Florey, ed.. Academic Press. Generally administered in combination with sulfamethoxazole the most common dosage forms are tablet, oral suspension and intravenous solution. The adult dose of TMP alone is 100 mg twi daily; TMP-S is generally available as 80 mg TMP plus 200 mg sul SUBSTITUTESHEET per dose. There is currently no oral liquid TMP-only product available on the market, although there are TMP-only tablet products. "Physician's Desk Reference", 45th Edition, Medical Economics Company. Given the facts that (1) fixed combination drugs are generally less desirable than individual drug dosing, (2) that the microbial activity spectrum of the two drugs is essentially equivalent, and (3) recent studies indicate that T alone is as therapeutically effective as the combination thera it appears advantageous to develop such a product, especially f pediatric use. "Trimethoprim in Pediatric Urinary Tract Infections", Child Nephrology and Urology, 89 (9), 77-81 (1988) From the perspectives of ease of use, accuracy of dose, an bioavailability, oral liquid dosage forms are generally preferr to be in the form of a solution. The general disadvantage of t oral solution is the tendency toward accentuating disagreeable taste contributed by the drug itself. From the perspective of taste, oral liquid dosage forms ar generally preferred to be in the form of a suspension which ten to mask the taste of the drug. The general disadvantages of th oral suspension are reduced accuracy and precision in dosing an reduced or delayed bioavailability. SUBSTITUTESHEET Especially for pediatric use, where, doses are relatively small, accuracy and precision of dose is extremely important. this reason, the preferable oral liquid form for TMP is the solution rather than the suspension. SUMMARY OF THE INVENTION The desire for an oral solution dosage form of TMP is complicated by the fact that it is a bitter compound with poor solubility in water. It is not possible to form a solution of in water at a sufficiently high concentration so as to provide proper dose. Further, the bitterness of the drug must be maske to provide appropriate palatability. The problem of solubility in water has been addressed in t case of the injection dosage form by the use of a high concentration of propylene glycol and alcohol as co-solvents, t drug being sufficiently soluble in the combination. However, s combination is extremely bitter and unpleasant tasting, making i completely unacceptable for oral use. The presence of propylene glycol, in fact, enhances the bitterness of the drug. Further, the use of alcohol is undesirable in pediatric formulations. It was, therefore, an objective of the invention to discove a method of solubilization of TMP in water which would permit dissolving a sufficient concentration of the drug while, at the - 3 - SUBSTITUTE SHEET same time, providing a basis for appropriate sweetening and flavoring in order to make the combination acceptably palatable. These and other objectives are achieved by the present invention which is directed to a pharmaceutical composition consisting of a palatable oral solution which contains trimethoprim in a suitable concentration for pediatric dosing. More specifically, the aqueous pharmaceutical composition is a combination of a sweetener, a flavoring, physiologically acceptable antimicrobial preservatives, and a vehicle of suitabl acid strength to permit the dissolving of trimethoprim at the appropriate concentration. The trimethoprim is present in the aqueous pharmaceutical composition at a concentration of at leas 1.25 mg to about 10 mg, and preferably 5 mg, per mL relative to the volume of solution. The composition further has a pH of les than 6.0. DETAILED DESCRIPTION OF THE INVENTION The composition of this invention is designed to be a palatable solution which is capable of delivering a therapeutic dose of trimethoprim in a form which is readily and rapidly absorbed from the gastrointestinal tract. The sweetener of the composition may be any natural or synthetic compound, or combination of compounds, which provides adequate sweetening to overcome the bitterness of the drug. - 4 - SUBSTITUTE SHEET Natural sweeteners include carbohydrates such as sucrose, dextrose, fructose, invert sugar, mannitol, sorbitol, and the like. Synthetic sweeteners include saccharin, aspartame, cyclamates, and other so-called artificial sweeteners familiar t those of skill in the art. However, the inventors early researc utilizing cosolvents such as alcohol, polyethylene glycols (PEG) propylene glycol, glycerin, and the like, proved fruitless in th the taste imparted by these solvents was additive to the already bad taste of the trimethoprim. The flavoring of the composition may be any natural or synthetic compound, or combination of compounds, which provides acceptable taste to overcome the blandness of the base composition. Such flavorings include bubble gum, grape, cherry, berry, citrus, other fruits, peppermint, spearmint, other mints, vanilla, chocolate, and the like, familiar to those of skill in the art. The antimicrobial preservatives of the composition include the derivatives of parahydroxybenzoic acid such as methyl parabe propyl paraben, butyl paraben, and the like, benzoic acid and it derivatives such as sodium benzoate, benzyl alcohol, and other compounds approved for use as preservatives in orally administer drug products. The vehicle of the composition includes water of suitable purity for use in orally administered drug products, and a stron SUBSTITUTE SHEET salt-forming acid of suitable strength to impart solubility of trimethoprim and to adjust the hydrogen ion concentration of th composition to a pH of less than 6.0, typically using acid, suc as hydrochloric acid or sulfuric acid. The preferred pH is in range of 4.0 to 6.0. The concept of using a strong acid to improve the solubili of TMP in order to achieve sufficient concentration without the use of non-aqueous cosolvents is critical to the formulation, since this permits appropriate sweetening and flavoring to allo for oral use. R Dahlin, C McDonald and VB Sunderland, "Solubilities and intrinsic dissolution rates of sulphamethoxaz and trimethoprim". Journal of Pharmacy and Pharmacology, 39, 246-251 (1987) discusses dissolution testing of TMP-sulfa table The data showed that the solubility of TMP is markedly higher between. pH 1.5 and 5.5, decreasing quickly above and below this range. It was shown that solubility remained poor at all pH's between 2 and 10 when adjusted with buffers of tart ate, acetat phosphate and borate. The inventors interpreted this to indica that pH adjustment alone was not sufficient to bring about dissolution, but that a strong salt-forming acid (such as hydrochloric acid or sulfuric acid) is necessary. On this basis the inventors studied the effect of using strong acid to solubilize the TMP and permit the formulation of a taste-acceptable solution dosage form. As part of this study, t inventors discovered that the use of weak acid buffers was - 6 - SUBSTITUTESHEET insufficient to bring about dissolution of TMP at a concentratio great enough to achieve therapeutic dosage levels. In the preferred method of preparing the composition, trimethoprim is mixed with purified water at 55°C, sufficient ac is added, and then the solution is mixed until completely dissolved. While cooling to room temperature, additional acid i added to adjust the pH to approximately 4.2. The preservative (e.g., methyl and propyl paraben dissolved in 3% propylene glyco is added while mixing continues. The sweetener (e.g., sucrose dissolved in water) is added while mixing continues. The artificial sweetener (e.g., sodium saccharin) and the flavoring (e.g., bubble gum flavor) are added while mixing continues. The remaining purified water, possibly containing a suitable buffer mixture to ensure maintenance of the pH of the final mixture at 4.0 to 6.0, is added to bring the composition to its final volum EXAMPLES Example 1 The following example describes the preparation of the TMP composition. - 7 - SUBSTITUTE SHEET Procedure (per liter) 1. Heat 500 mL of water to 50-55°C, and add 5.0 g of trimethoprim. 2. Without additional heating and while stirring, add hydrochloric acid to pH of 4.2-4.4, with pH meter temperat compensation, or 4.5 without meter compensation. This wil require approximately 16 L of IN HC1 per liter. 3. When the solution is clear, add methyl and propyl parab dissolved in propylene glycol. 4. Add 450 mL simple syrup. 5. Cool to room temperature. 6. Add sodium saccharin and bubble gum flavor. 7. Bring to 1 liter volume with water. - 8 - SUBSTITUTE SHEET The TMP composition gives the following characteristics: Trimethoprim, Micronized, USP 5.000 Purified Water, USP approx 500 Hydrochloric Acid, IN approx 16 Methyl Paraben, NF 0.500 Propyl Paraben, NF 0.050 Propylene Glycol, USP 30.000 Simple Syrup, USP 450.000 Saccharin Sodium, USP 1.500 N/A Bubble Gum Flavor, Crompton & Knowles #F1, W/S, All,236 2.000 Example 2 Physical Properties A sample of the composition was subjected to freezing at a temperature of less than 0°C for several days, allowed to thaw a room temperature, refrozen, rethawed, refrozen, and rethawed again. A visual examination of the sample revealed no crystallization of any substances from solution. A sample of the composition was subjected to storage in a refrigerator at a temperature of less than 10°C for several week A visual examination of the sample revealed no crystallization o any substances from solution. - 9 - SUBSTITUTESHEET A sample of the composition was subjected to storage in a incubator at a temperature of 45°C for several weeks. A visua examination of the sample revealed no discoloration or crystallization of any substances from solution. Microbiological Properties A sample of the composition was subjected to preservative effectiveness testing by a method similar to that described in volume 22 United States Pharmacopeia, "Antimicrobial Preservati - Effectiveness," Test 51 (1990). The composition met the prescribed criteria at the 48 hour time period. Chemical Stability Properties A sample of the composition was subjected to storage at ro temperature for several weeks. Chemical analysis of the sample revealed no degradation of trimethoprim and no physical evidenc of deterioration with respect to color, flavor, or sweetness. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarit of understanding, it will be obvious to one skilled in the art that certain changes and modifications may be practiced within t scope of the appended claims. - 10 -

Claims: WHAT IS CLAIMED IS: 1. An aqueous pharmaceutical composition consisting essentially of about 1.25 mg to about 10 mg trimethoprim per mL (wt/vol) of solution and a compound of suitable acid strength to permit the dissolving of trimethoprim at the appropriate concentration, said composition having a pH of less than 6.0. 2. The aqueous pharmaceutical composition of claim 1 wherei said trimethoprim concentration is 5 mg per mL. 3. The aqueous pharmaceutical composition of claim 1 wherei said compound of suitable acid strength is hydrochloric acid or sulfuric acid. 4. The aqueous pharmaceutical composition of claim 1 wherei the pH range is from 4.0 to 6.0. 5. The aqueous pharmaceutical composition of claim 1 wherei the composition is especially suitable for pediatric oral use. 6. A method of making an aqueous pharmaceutical composition for oral administration comprising dissolving trimethoprim with compound of sufficient acid strength to permit said dissolving o trimethoprim at a concentration of at least 1.25 mg trimethoprim per L to about 10 mg trimethoprim per mL (wt/vol) of solution, said composition having a pH of less than 6.0. - 11 - SUBSTITUTESHEET 7. The method of claim 6 wherein said trimethoprim concentration is 5 mg per L. 8. The method of claim 6 wherein said compound of suitable acid strength is hydrochloric acid or sulfuric acid. 9. The method of claim 6 wherein the pH range is from 4.0 6.0. 10. A method of treating a patient suffering from a bacter infection comprising administering to said patient with a therapeutically effective antibacterial treatment amount of a compound consisting essentially of at least 1.25 mg trimethopri and to about 10 mg trimethoprim per mL (wt/vol) of solution and compound of suitable acid strength to permit the dissolving of trimethoprim at the appropriate concentration, said composition having a pH of less than 6.0. 11. The method of claim 10 wherein said trimethoprim concentration is 5 mg per mL and wherein said composition is especially suitable for pediatric oral use. - 12 - SUBSTITUTESHEET

Inventors: CLEMENTE EMMETT, MENDES ROBERT W, PATHAK NITIN, CLEMENTE, EMMETT, MENDES, ROBERT, W., PATHAK, NITIN
Applicants: ASCENT PHARMA INC, ASCENT PHARMACEUTICALS, INC.
Application year: 1992
Main classification: A61K31
IPC codes: A61K9, A61K31, A61P31